DDInter1055 DDInter176
Levofloxacin is a fluoroquinolone antibiotic and the optical S-(-) isomer of racemic [ofloxacin]. It reportedly carries 8 to 128-fold more activity against both gram-negative and gram-positive bacteria compared to R-(+)-ofloxacin and remains stereochemically stable following administration (i.e. it does not invert to the inactive isomer). Levofloxacin, along with other quinolones such as [gatifloxacin] and [moxifloxacin], is a member of the third generation of fluoroquinolones, colloquially referred to as the "respiratory quinolones" due to improved activity against gram-positive bacteria commonly implicated in respiratory infections.[A31453,A190756] Levofloxacin was first approved by the FDA in 1996, and was approved in Canada and several South American countries soon after.
High levels of LDL cholesterol (LDL-C) are a major risk factor for cardiovascular events. Caused by genetic mutations or lifestyle factors, hypercholesterolemia can significantly reduce quality of life and increase the risk of mortality from cardiovascular disease. About 1 in 4 patients, or 15 million Americans with elevated LDL-C, are insufficiently managed with maximally tolerated statin therapy alone, requiring additional treatment for hypercholesterolemia. Bempedoic acid is first-in-class adenosine triphosphate-citrate lyase (ACL) inhibitor used once a day for reducing LDL cholesterol levels in statin-refractory patients.[L12144,L12147] It was developed by Esperion Therapeutics Inc. and approved by the FDA on February 21, 2020. A combination product of bempedoic acid and [ezetimibe] was approved on February 26, 2020 for increased control of LDL cholesterol levels in patients experiencing refractory elevations despite previous statin treatment.[L12144,L12150]
Levofloxacin {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Fexofenadine
Fexofenadine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bempedoic acid
Levofloxacin {u} (Compound) causes {v} (Side Effect) Agitation
Agitation {u} (Side Effect) is caused by {v} (Compound) Fexofenadine
Fexofenadine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bempedoic acid
Levofloxacin {u} (Compound) causes {v} (Side Effect) Agitation
Agitation {u} (Side Effect) is caused by {v} (Compound) Budesonide
Budesonide {u} may lead to a major life threatening interaction when taken with {v} Bempedoic acid
Levofloxacin {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Prednisolone
Prednisolone {u} may lead to a major life threatening interaction when taken with {v} Bempedoic acid
Levofloxacin {u} (Compound) downregulates {v} (Gene) DNMT3A
DNMT3A {u} (Gene) is downregulated by {v} (Compound) Repaglinide
Repaglinide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bempedoic acid
Levofloxacin {u} (Compound) downregulates {v} (Gene) DNMT3A
DNMT3A {u} (Gene) is downregulated by {v} (Compound) Betamethasone
Betamethasone {u} may lead to a major life threatening interaction when taken with {v} Bempedoic acid
Levofloxacin {u} (Compound) resembles {v} (Compound) Gatifloxacin
Gatifloxacin {u} may lead to a major life threatening interaction when taken with {v} Repaglinide
Repaglinide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bempedoic acid
Levofloxacin {u} (Compound) resembles {v} (Compound) Gatifloxacin
Gatifloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Irinotecan
Irinotecan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bempedoic acid
Levofloxacin {u} (Compound) resembles {v} (Compound) Gatifloxacin
Gatifloxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Methotrexate
Methotrexate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bempedoic acid
Levofloxacin {u} (Compound) resembles {v} (Compound) Enoxacin
Enoxacin {u} may lead to a major life threatening interaction when taken with {v} Repaglinide
Repaglinide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bempedoic acid
Levofloxacin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Fexofenadine (Compound) and Fexofenadine may cause a moderate interaction that could exacerbate diseases when taken with Bempedoic acid
Levofloxacin (Compound) causes Agitation (Side Effect) and Agitation (Side Effect) is caused by Fexofenadine (Compound) and Fexofenadine may cause a moderate interaction that could exacerbate diseases when taken with Bempedoic acid
Levofloxacin (Compound) causes Agitation (Side Effect) and Agitation (Side Effect) is caused by Budesonide (Compound) and Budesonide may lead to a major life threatening interaction when taken with Bempedoic acid
Levofloxacin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Prednisolone (Compound) and Prednisolone may lead to a major life threatening interaction when taken with Bempedoic acid
Levofloxacin (Compound) downregulates DNMT3A (Gene) and DNMT3A (Gene) is downregulated by Repaglinide (Compound) and Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Bempedoic acid
Levofloxacin (Compound) downregulates DNMT3A (Gene) and DNMT3A (Gene) is downregulated by Betamethasone (Compound) and Betamethasone may lead to a major life threatening interaction when taken with Bempedoic acid
Levofloxacin (Compound) resembles Gatifloxacin (Compound) and Gatifloxacin may lead to a major life threatening interaction when taken with Repaglinide and Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Bempedoic acid
Levofloxacin (Compound) resembles Gatifloxacin (Compound) and Gatifloxacin may cause a minor interaction that can limit clinical effects when taken with Irinotecan and Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Bempedoic acid
Levofloxacin (Compound) resembles Gatifloxacin (Compound) and Gatifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Bempedoic acid
Levofloxacin (Compound) resembles Enoxacin (Compound) and Enoxacin may lead to a major life threatening interaction when taken with Repaglinide and Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Bempedoic acid